Drupal.behaviors.print = function(context) {window.print();window.close();}>
Leerink Swann Initiates Coverage of Fluidigm
March 22, 2011
Leerink Swann Initiates Coverage of Fluidigm
The investment firm gave Fluidigm an "Outperform" rating and a valuation of between $17 and $18.
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Mizuho Starts Coverage of Fluidigm, BG Medicine with Buy Rating
August 31, 2012 / GenomeWeb Daily News
Fluidigm Places Price Range of $13.50 to $15.50 per Share on IPO
January 28, 2011 / GenomeWeb Daily News
Mizuho Downgrades Fluidigm to Neutral, Trims Estimates
October 9, 2012 / GenomeWeb Daily News
Fluidigm Inks Singapore, Thailand Distribution Pact
October 18, 2011 / GenomeWeb Daily News
Fluidigm, BD Biosciences to Co-host Seminars on Combined Technologies
August 4, 2011 / GenomeWeb Daily News